Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
about
A chemically labeled cytotoxic agent: two-photon fluorophore for optical tracking of cellular pathway in chemotherapySynthesis, characterization and stability of a luteinizing hormone-releasing hormone (LHRH)-functionalized poly(amidoamine) dendrimer conjugate.Peptide analogs in the therapy of prostate cancer.Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomesAEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.Receptor-targeting phthalocyanine photosensitizer for improving antitumor photocytotoxicity.Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with Luteinizing Hormone-Releasing Hormone (LHRH) peptide.Synthesis and evaluation of novel gonadotropin-releasing hormone receptor-targeting peptides.Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cellsInhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.Luteinizing hormone-releasing hormone antagonists.Receptor-mediated tumor targeting based on peptide hormones.Peptide-mediated targeted drug delivery.Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.Possibilities to increase the effectiveness of doxorubicin in cancer cells killing.Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).Gonadotropin-releasing hormone targeting for gonadotroph ablation: an approach to non-surgical sterilization.Natural product and natural product derived drugs in clinical trials.Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice.Drug delivery and release systems for targeted tumor therapy.GnRH and GnRH receptors in the pathophysiology of the human female reproductive system.Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites.Gonadotropin-releasing hormone receptor-targeted paclitaxel-degarelix conjugate: synthesis and in vitro evaluation.A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.Peptides and Drug Delivery.Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH.
P2860
Q30779111-DC9BC1F2-1317-4FD3-94BA-15B970ED424AQ33313432-3499B92B-4E76-44CA-932C-A47CD1254295Q34057795-5E4D28C4-ADC3-44F2-8D31-AC9C60A1EA74Q34101055-585F5336-C1E3-4BB6-A4E2-B3913D3FBB9FQ34170191-FCFD64C0-B5D4-4957-B4BB-8F903CE80566Q34274245-09F4B896-42C5-4BBB-ABDE-D9579BBEA186Q34302297-A5A0B5D9-7A0B-4DCC-898F-E4C65920EB66Q34772221-B5350B0D-B729-4D46-90C3-19C1538829D1Q34840155-4C1A4A30-F5BD-4B92-84FF-55DA3D212ABEQ34979199-82A58D0F-9567-4C65-9469-7AD70C1DA684Q35162175-A4F3F130-39C6-4940-9F00-B7F3EB2425D3Q35169098-3D963DC3-1561-4B6A-ABEF-B25CE2AF5157Q35891113-F2CF8444-F0BE-4945-BF73-7268B0971A93Q35959684-00951961-9DC9-4434-BFA2-E53E76A389EEQ35997236-C0F2658C-9166-4079-9187-529B2295092BQ36202016-C41E2290-EA53-48E1-96DD-40C7266F2FE8Q36748502-46051872-06D4-42A2-ADAE-2817CB277015Q36948906-36C3BDBC-6714-455E-A3A5-95BFF1D5FEDCQ37029375-76BA53ED-A672-4F93-AE41-21151BBBF3EDQ37083440-1A031ECC-3E95-4E0E-9B91-C3F04BCB91E0Q37196815-4ECEA9A8-DA6C-4DA8-BCB3-D852F377BDC8Q37584911-589AE6B3-F13B-48E1-AA4E-5DC2535C8D27Q37638747-88505AD4-434B-45E2-91F3-8FF238CB5DE8Q37641368-233F69BA-7E82-4411-96B3-B3648E6F5615Q37785045-9A778C65-9EF7-42F6-8C3C-2C5DFFEA6D79Q37859389-190FF779-28DF-4B48-B989-3BA7B3923A60Q37937579-9ACF7745-F541-439C-B809-A554CBBA4848Q38007373-4ECBF211-223A-4BD5-B5F7-0F2EDA534586Q38029046-3D7E62D1-13FF-457B-9626-24271EFD8A39Q38247457-6F941E32-0BB2-46A5-81F8-39BEE947E407Q38311828-80DA22BC-98EC-41C6-BD23-2C292BBB886CQ38363691-E843A4D1-8414-4B64-8637-A17BFF768EB0Q38682630-5477851C-C757-4753-9A05-0C59A14EBD78Q38882916-21B3D198-2BCD-4293-BA19-5032B6012E4AQ39267156-CF153439-1716-4B7D-AC0A-CFE7D06DAD19Q39643108-7FA65352-2B1B-469B-BAC1-BCD9E2EC897FQ42828662-C5DFBBC5-CC1C-4A93-8BDD-1622EF5648A8Q47369407-2A8AD526-0DA6-4102-A4A7-2C16ACC45921Q47590591-BEE499F3-71B8-494B-AA9F-B38E1CCAB230Q48656281-69FBF9F1-89AF-44A2-B272-78D6B9BD341D
P2860
Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
description
1996 nî lūn-bûn
@nan
1996 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@ast
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en-gb
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@nl
type
label
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@ast
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en-gb
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@nl
prefLabel
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@ast
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en-gb
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@nl
P2093
P2860
P921
P356
P1476
Cytotoxic analogs of luteinizi ...... ive 500-1000 times more potent
@en
P2093
A Jungwirth
A V Schally
K Szepeshazi
M Miyazaki
P2860
P304
P356
10.1073/PNAS.93.14.7269
P407
P577
1996-07-09T00:00:00Z